Streetbeat News

Stock Prices

CMND

Clearmind Medicine Inc (NYSE:CMND) stock rose after announcing positive results from pre-clinical trials for cocaine addiction treatment using its psychedelic molecule MEAI. The company, which focuses on developing psychedelic-derived therapeutics, also filed a patent application related to cocaine addiction in collaboration with SciSparc's CannAmide. The CEO highlighted the potential paradigm shift in treating cocaine addiction, a condition currently lacking dedicated treatments.

Portfolio Pulse from Adam Eckert

December 05, 2023 | 3:21 pm

BAC

SPY

Bank of America CEO Brian Moynihan appeared live on CNBC to discuss consumer spending trends. The discussion likely covered the bank's insights into spending patterns, which could reflect the broader economic health and consumer confidence.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 3:20 pm

FERG

Ferguson PLC (NYSE:FERG) shares rose after reporting Q1 FY24 results with sales of $7.71 billion, surpassing the $7.65 billion consensus. Despite a 2.8% Y/Y sales decline due to lower residential sales, adjusted EPS of $2.65 beat the $2.62 consensus. The U.S. and Canada businesses saw organic revenue declines, and the company experienced a slight contraction in gross and adjusted operating margins. Ferguson declared a 5% increased quarterly dividend and repurchased $108 million in shares. The company reiterated its FY24 guidance, expecting flat net sales and an adjusted operating margin between 9.2% and 9.8%. FERG shares traded up 4.46% at $175.75.

Portfolio Pulse from Lekha Gupta

December 05, 2023 | 3:17 pm

CLF

GLJ Research analyst Gordon Johnson has reiterated a Sell rating on Cleveland-Cliffs (NYSE:CLF) and reduced the price target from $13.44 to $11.45.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 3:16 pm

ROST

Ross Stores Inc. (NASDAQ:ROST) stock price is currently $132.31, having decreased by 0.26% in the current market session. Over the past month, ROST's stock has risen by 7.29%, and over the past year, by 14.55%. The article discusses the company's P/E ratio, which at 26.32 is lower than the Specialty Retail industry average of 27.31. This could indicate that the stock is undervalued or that shareholders have lower growth expectations.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 3:15 pm

CMND

CYBN

PSIL

SEEL

SPRC

The Department of Defense Health Agency is funding a trial for PTSD treatment using Seelos Therapeutics' intranasal ketamine, SLS-002. Cybin Inc. reported strong efficacy in its Phase 2 trial of psilocybin derivative CYB003 for Major Depressive Disorder. Clearmind Medicine announced results from a pre-clinical trial combining its MEAI treatment with SciSparc's PEA for various disorders. Clearmind also underwent a reverse stock split to comply with Nasdaq's minimum bid price rule. Beckley Retreats is launching a new psilocybin retreat program, and Mindbloom is introducing a ketamine therapy program. Seelos Therapeutics launched a public offering, and other companies reported financial results or updates. The AdvisorShares Psychedelics ETF and several psychedelics stocks' trading performance are also highlighted.

Portfolio Pulse from Lara Goldstein

December 05, 2023 | 3:12 pm

CMND

Clearmind Medicine shares resumed trading after a circuit breaker halt. The halt was triggered by a significant move in the stock price, which is a common protective measure in the stock market to prevent excessive volatility.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 3:08 pm

INTR

Inter&Co, a financial services company, has surpassed 30 million clients, indicating significant growth and progress towards its five-year business plan. This milestone suggests a strong market presence and potential for future expansion.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 3:05 pm

JNJ

OGN

Johnson & Johnson (NYSE:JNJ) is distributing a dividend of $1.19 per share with an annualized yield of 3.12%. Shareholders as of November 20, 2023, are eligible. The company has shown a positive trend in dividend per share growth from $3.75 in 2019 to $4.45 in 2022, and earnings per share growth from $8.77 to $9.94 over the same period. This indicates a strong financial position and potential for future dividend increases. Organon (NYSE:OGN) has the highest annualized dividend yield in the industry at 9.47%.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 3:05 pm

FNF

L

Loews Corporation (NYSE:L) has issued a dividend payout of $0.06 per share with an annualized yield of 0.38%. The ex-dividend date was November 21, 2023, and the dividend is payable on December 05, 2023. Loews has maintained a consistent dividend per share of $0.25 from 2019 to 2022, indicating a stable dividend policy. The company's earnings per share have grown from $3.05 in 2019 to $4.00 in 2022, suggesting a strong financial health and potential for future dividend increases. Loews's dividend yield is moderate compared to industry peers, with Fidelity National Financial (NYSE:FNF) having a higher yield at 4.22%.

Portfolio Pulse from Benzinga Insights

December 05, 2023 | 3:05 pm